Royce & Associates LP Boosts Stock Holdings in Entrada Therapeutics, Inc. $TRDA

Royce & Associates LP lifted its position in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 54.8% in the 3rd quarter, Holdings Channel.com reports. The fund owned 345,507 shares of the company’s stock after buying an additional 122,256 shares during the quarter. Royce & Associates LP’s holdings in Entrada Therapeutics were worth $2,004,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in TRDA. Geode Capital Management LLC lifted its position in Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after acquiring an additional 42,479 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Entrada Therapeutics by 735.0% in the third quarter. JPMorgan Chase & Co. now owns 133,878 shares of the company’s stock worth $776,000 after purchasing an additional 117,844 shares during the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Entrada Therapeutics by 435.1% during the second quarter. Qube Research & Technologies Ltd now owns 133,730 shares of the company’s stock valued at $899,000 after purchasing an additional 108,737 shares in the last quarter. First Trust Advisors LP boosted its position in shares of Entrada Therapeutics by 3.6% during the second quarter. First Trust Advisors LP now owns 75,120 shares of the company’s stock valued at $505,000 after buying an additional 2,631 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in Entrada Therapeutics by 10.8% in the 2nd quarter. American Century Companies Inc. now owns 75,094 shares of the company’s stock worth $505,000 after buying an additional 7,301 shares in the last quarter. 86.39% of the stock is currently owned by hedge funds and other institutional investors.

More Entrada Therapeutics News

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and maintained a $20 price target, which provides upside support despite the estimate cuts. MarketBeat TRDA
• Neutral Sentiment: HC Wainwright nudged its Q1 2026 EPS estimate slightly less negative (from -$1.20 to -$1.12), a small improvement in the near-term outlook that is unlikely to materially change fundamentals.
• Neutral Sentiment: Reported short interest shows 0 shares and a 0.0 days-to-cover figure; the report includes NaN values and looks unreliable, so it should not be treated as meaningful short-pressure evidence.
• Negative Sentiment: HC Wainwright cut multiple 2026 quarterly and full-year EPS forecasts (Q2 2026 to -$1.30 from -$1.24; Q3 2026 to -$1.12 from -$0.98; Q4 2026 to -$0.96 from -$0.81; FY2026 to -$4.49 from -$4.21), increasing near-term expected losses — a likely catalyst for downside pressure on the stock.
• Negative Sentiment: The firm also projects FY2027 EPS of -$3.18 and trimmed some 2027 quarterly expectations, keeping the multi-quarter loss profile intact; these larger negative earnings revisions weigh on investor sentiment despite the Buy rating.

Entrada Therapeutics Stock Down 7.0%

NASDAQ TRDA opened at $11.62 on Friday. Entrada Therapeutics, Inc. has a 52 week low of $4.93 and a 52 week high of $12.93. The firm has a market capitalization of $444.81 million, a P/E ratio of -3.36 and a beta of -0.12. The company has a 50-day moving average price of $11.01 and a 200-day moving average price of $8.64.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.38. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. As a group, equities research analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on TRDA. Guggenheim raised Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Roth Mkm set a $13.00 price objective on shares of Entrada Therapeutics in a report on Thursday, November 6th. Oppenheimer began coverage on shares of Entrada Therapeutics in a report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.50.

Entrada Therapeutics Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.